Date: 03/09/2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Scrip Code: 514330/Scrip ID: ONEGLOBAL

Subject: Outcome of Board Meeting held on Thursday, 3rd September, 2026

Ref: Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations")

Dear Sir/Madam,

Pursuant to Regulation 30, and other applicable provisions of SEBI LODR Regulations, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e., Thursday, 3rd September, 2026, have *inter-alia,* considered and approved the following(s):

1. **Appointment of M/s. S D P M & Co; (FRN:126741W) Chartered Accountants, as the Statutory Auditors of the Company:**

   Based on the recommendation of the Audit Committee, the Board of Directors of the Company recommended appointment of M/s. S D P M (FRN:126741W) Chartered Accountants, as the Statutory Auditors of the Company to hold the office for a second term of 5 (five) consecutive years from the conclusion of 34th Annual General Meeting **("AGM")** of the Company till the conclusion of the 39th AGM, subject to the approval of the Members of the Company and other statutory requirements.

   Details as required under Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (or the master circular in force on the date of filing), is enclosed as **'Annexure A'.**

2. **Appointment of M/s. Valawat & Associates, (FRN: 434660) Chartered Accountants, as the Internal Auditors of the Company:**

   Based on the recommendation of the Audit Committee, the Board of Directors of the Company recommended appointment of M/s. Valawat & Associates, (FRN: 434660) Chartered Accountants, as the Internal Auditors of the Company for the Financial Year 2026-27.

   Details as required under Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (or the master circular in force on the date of filing), is enclosed as **'Annexure B'.**

3. **Approval for Acquisition 51% Equity Stake in Matrix Labs Diagnocare Private Limited and Matrix Labs Private Limited, respectively and Issuance of Equity Shares on Preferential Basis:**

   The Board of Directors of the Company, has approved, subject to the approval of the Members of the Company and such other statutory and regulatory approvals as may be required, the acquisition of 51% equity stake in each of Matrix Labs Diagnocare Private Limited **("MLDPL")** and Matrix Labs Private Limited **("MLPL")**.

   In this regard, the Company proposes to acquire 13,321 equity shares of MLDPL and 2,550 equity shares of MLPL, representing 51% of the total issued, subscribed and paid-up equity share capital of MLDPL and MLPL, respectively.

The aforesaid equity shares are proposed to be acquired from Mr. Suresh and Ms. Nithya S in the case of MLDPL and from Mr. Suresh in the case of MLPL, for a non - cash consideration of Rs. 35,97,81,800/- (Rupees Thirty-Five Crore Ninety-Seven Lakh Eighty-One Thousand Eight Hundred Only) and Rs. 3,56,35,320/- (Rupees Three Crore Fifty-Six Lakh Thirty-Five Thousand Three Hundred Twenty Only), respectively.

The consideration for the proposed acquisition shall be discharged by way of issuance and allotment of equity shares of the Company on a preferential basis, in consideration other than cash, pursuant to a share swap arrangement. Accordingly, the Company proposes to issue, offer and allot 6,01,760 (Six Lakh One Thousand Seven Hundred Sixty Only) and 48,480 (Forty Thousand Forty Eighty), equity shares of the Company to Mr. Suresh and Ms. Nithya S, respectively, against the acquisition of 51% equity stake in MLDPL and 64,440 (Sixty-Four Thousand Four Hundred Forty Only) equity shares of the Company to Mr. Suresh against the acquisition of 51% equity stake in MLPL.

The equity shares proposed to be issued shall have a face value of Rs. 10/- each and shall be issued at a price of Rs. 553/- (Rupees Five Hundred Fifty-Three Only) per equity share, including premium aggregating to Rs. 39,54,17,120/-(Rupees Thirty-Nine Crore Fifty-Four Lakh Seventeen Thousand One Hundred Twenty Only), which shall not be less than the price determined in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 **("SEBI ICDR Regulations")**.

The disclosures required pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations") and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as amended from time to time or any master circular in force as on the date of filing, are enclosed herewith as **'Annexure C1 & C2'** respectively.

4. Execution of Share Purchase Agreements for Acquisition of 51% Equity Stake:

In furtherance of the aforesaid acquisition, the Company has entered into the following Share Purchase Agreements **("SPAs")** dated 3rd September, 2026

a) Matrix Labs Diagnocare Private Limited ("MLDPL"):

An SPA has been entered into between One Global Service Provider Limited, Mr. Suresh, Ms. Nithya S and Matrix Labs Diagnocare Private Limited for the acquisition by the Company of 13,321 equity shares of MLDPL, representing 51% of the total issued, subscribed and paid-up equity share capital of MLDPL.

b) Matrix Labs Private Limited ("MLPL"):

An SPA has been entered into between One Global Service Provider Limited, Mr. Suresh and Matrix Labs Private Limited for the acquisition by the Company of 2,550 equity shares of MLPL, representing 51% of the total issued, subscribed and paid-up equity share capital of MLPL.

Details as required under Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (or the master circular in force on the date of filing), are enclosed herewith as **'Annexure D1 and D2'** respectively.

5. Preferential Issue of Equity Shares for Consideration Other than Cash:

The Company proposes to issue, offer and allot 7,15,040 (Seven Lakh Fifteen Thousand Forty Only) fully paid-up equity shares of the Company on a preferential basis, having a face value of Rs. 10/- each, at an issue price of Rs. 553/- (Five Hundred Fifty-Three Only) per equity share, including premium **("Allotment Shares")**, to Mr. Suresh and Ms. Nithya S, towards discharge of the non-cash consideration payable by the Company for the acquisition of 13,321 (Thirteen Thousand Three Hundred Twenty-One Only) equity shares of Matrix Labs Diagnocare Private Limited **("MLDPL")**, representing 51% of its total issued, subscribed and paid-up equity share capital, and to Mr. Suresh, towards discharge of the non-cash consideration payable by the Company for the acquisition of 2,550 (Two Thousand Five Hundred Fifty Only) equity shares of Matrix Labs Private Limited **("MLPL")**, representing 51% of its total issued, subscribed and paid-up equity share capital (collectively, the **"Purchase Shares"**).

Details as required under Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (or the master circular in force on the date of filing), is enclosed as **'Annexure – E'.**

6. **Increase of Authorised Share Capital of the Company:**

Increase of Authorised Share Capital of the Company from 25,05,00,000/- (Rupees Twenty-Five Crore Five Lakh Only) divided into 2,50,50,000 (Two Crore Fifty Lakh Fifty Thousand) Equity Shares of Rs. 10/- (Rupees Ten Only) each, to Rs.50,00,00,000/- (Rupees Fifty Crore Only) divided into 5,00,00,000 (Five Crore) Equity Shares of Rs. 10/- (Rupees Ten Only) each and consequent alteration of Capital Clause of the Memorandum of Association of the Company.

Details as required under Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (or the master circular in force on the date of filing), is enclosed as **'Annexure – F'.**

7. **Convening of 34th Annual General Meeting:**

Convening of 34th Annual General Meeting **("AGM")** of the Members of the Company on Tuesday, at 29th September, 2026, 02:00 P.M. through Video Conferencing **("VC")**/Other Audio -Visual Means **("OAVM")**.

The Board meeting commenced at 05:00 P.M. and concluded at 11:15 P.M.

This is for your information and records.

Kindly take the same on record.

Thanking you,
Yours faithfully,

For ONE GLOBAL SERVICE PROVIDER LIMITED
(Formerly known as Overseas Synthetics Limited)

Sanjay Sanjya

Sanjay Lalbhadur Upadhaya
Managing Director
DIN: 07497305

ONE GLOBAL SERVICE PROVIDER LIMITED

Encl: As above

ANNEXURE A

Disclosure regarding Appointment of Statutory Auditor

(Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015 read with Schedule III Part A, Para A and Section 148 of the Companies Act, 2013)

Sr.No.	Particulars	Details
1.	**Reason for change viz. appointment**	M/s. S D P M & Co; (FRN:126741W) Chartered Accountants, as the Statutory Auditors of the Company until the conclusion of the 34th Annual General Meeting **("AGM")** of the Company, marking the completion of their first term. M/s. S D P M & Co; (FRN:126741W) Chartered Accountants, as the Statutory Auditors of the Company from the conclusion of 34th AGM of the Company till the conclusion of the 39th AGM, subject to the approval of the Members of the Company and other statutory requirements.
2.	**Date of Appointment**	Based on the recommendation of the Audit Committee, the Board of Directors at its meeting held today approved the appointment of M/s. S D P M & Co; (FRN:126741W) Chartered Accountants, as the Statutory Auditors of the Company from the conclusion of 34th AGM of the Company till the conclusion of the 39th AGM, subject to the approval of the Members of the Company and other statutory requirements.
3.	**Brief Profile (in case of appointment)**	S D P M & Co., a partnership firm is providing services to Corporates, Non- Corporates, Individuals, trusts and other bodies. The firm has developed immense strength in auditing Corporate, advisory, planning and finance arrangements, bank audit, capital market audit etc.
4.	**Disclosure of relationships between directors (in case of appointment)**	Not Applicable

ANNEXURE B

Disclosure regarding Appointment of Internal Auditor

(Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015 read with Schedule III Part A, Para A and Section 148 of the Companies Act, 2013)

Sr.No.	Particulars	Details
1.	**Reason for change viz. appointment**	Pursuant to resignation of M/s. Rushil Soni & Co., Chartered Accountants, as the Internal Auditors of the Company on 14th August, 2026.
2.	**Date of Appointment**	Based on the recommendation of the Audit Committee, the Board of Directors at its meeting held today approved the appointment of M/s. Valawat & Associates, (FRN: 434660) Chartered Accountants, as the Internal Auditors of the Company for the Financial Year 2026-27.
3.	**Brief Profile (in case of appointment)**	Valawat & Associates, established in 1987, is a Chartered Accountants firm based in Mumbai and Udaipur, offering a comprehensive range of services including bank audits, statutory audits, tax audits, and advisory solutions. We have strength of 15 employees includes qualified and semi-qualified CA's. Serving over 250 clients, the firm is empanelled with the Reserve Bank of India, the Comptroller and Auditor General of India, and has undergone Peer Review. With a blend of experienced and young professionals, Valawat & Associates delivers customized business solutions aimed at ensuring compliance and fostering client growth. Their dedication to providing high-quality, value-added services aligns with their mission to enhance business success at every stage of development.
4.	**Disclosure of relationships between directors (in case of appointment)**	Not Applicable

ANNEXURE C1

(Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, or the master circular in force on the date of filing)

Sr.No.	Particulars	Details
1.	**Name of the target entity, details in brief such as size, turnover etc.**	**Name**: Matrix Labs Diagnocare Private Limited **("MLDPL")** **Turnover as on 31st March, 2025:** Rs.171.30 Crore
2.	**Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired**	The proposed acquisition does not fall within the purview of related party transaction. Further, the promoter/promoter group/group companies of the Company do not have any interest in the entity being acquired.
3.	**Industry to which the entity being acquired belongs**	MLDPL belongs to the In-Vitro Diagnostics (IVD), Medical Diagnostics and Healthcare industry. The Company is engaged in providing diagnostic solutions and products, including immunology, HPLC, clinical automation, microbiology, hematology, biochemistry, homeostasis and point-of-care testing (POCT) solutions.
4.	**Disclosure of relationships between directors**	Not applicable
5.	**Objects and impact of acquisition (including but not limited to disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)**	The acquisition is proposed with an objective to strengthen the Company's presence in the healthcare, medical diagnostics and IVD sector, expand its diagnostic product and technology offerings, leverage the target entity's capabilities and market presence, achieve strategic and operational synergies and enhance long-term shareholder value.
6.	**Brief details of any governmental or regulatory approvals required for the acquisition.**	The proposed acquisition is subject to receipt of such statutory, regulatory and other approvals, consents and permissions as may be applicable to the transaction.
7.	**Indicative time period for completion of acquisition**	Up to 6 months, subject to receipt of necessary statutory and regulatory approvals and fulfilment of the terms and conditions of the definitive transaction documents.
8.	**Nature of consideration – whether cash consideration or share swap or any other form and details of the same**	The acquisition shall be undertaken by way of issuance and allotment of equity shares of the Company on a preferential basis for consideration other than cash through a share swap arrangement, for acquisition of up to 13,321 equity shares representing 51% of the diluted paid-up equity share capital of MLDPL.
9.	**Cost of acquisition and/or the price at which shares are acquired**	The consideration shall be discharged by way of issuance of 6,50,600 (Six Lakh Fifty Thousand Six Hundred Only) equity shares of the Company pursuant to the share swap

<table>
<tr><td></td><td></td><td>arrangement, as determined on the basis of the valuation reports and definitive transaction documents.</td></tr>
<tr><td>10.</td><td>Percentage of shareholding/control acquired and/or number of shares acquired</td><td>The Company proposes to acquire 13,321 (Thirteen Thousand Three Hundred Twenty-One Only) equity shares of MLDPL, representing 51% of the diluted paid-up equity share capital of the MLDPL. Upon completion of the transaction, MLDPL shall become a subsidiary of the Company.</td></tr>
<tr><td>11.</td><td>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)</td><td>MLDPL was incorporated on 15th September, 2023 and is engaged in the In-Vitro Diagnostics (IVD) and medical diagnostics business. The Company is headquartered in Chennai, Tamil Nadu, India and provides a range of diagnostic solutions covering Immunology, HPLC, Clinical Automation, Microbiology, Hematology, Biochemistry and Homeostasis, along with point-of-care testing solutions.

The Company's product portfolio includes diagnostic analysers and systems for clinical laboratories and point-of-care applications, and it also provides installation, training, preventive maintenance, corrective maintenance, remote diagnostics and other technical support services for IVD systems.

Date of Incorporation: 15th September, 2023

<table>
<tr><th>Financial Year</th><th>Turnover (Rs. in Crore)</th></tr>
<tr><td>2022-23*</td><td>--</td></tr>
<tr><td>2023-24</td><td>--</td></tr>
<tr><td>2024-25</td><td>171.30</td></tr>
</table>
*As the company was incorporate on 15th September, 2023

Country of presence:
India

Any other significant information:
Nil</td></tr>
</table>

Annexure C2

(Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, or the master circular in force on the date of filing)

Sr.No.	Particulars	Details
1.	**Name of the target entity, details in brief such as size, turnover etc**	**Name**: Matrix Labs Private Limited **(MLPL)** **Turnover as on 31st March, 2025:** Rs. 8.92 Crore
2.	**Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired**	The proposed acquisition does not fall within the purview of related party transaction. Further, the promoter/promoter group/group companies of the Company do not have any interest in the entity being acquired.
3.	**Industry to which the entity being acquired belongs**	MLPL belongs to the Medical Equipment and In-Vitro Diagnostics (IVD) industry and is engaged in the development, manufacture and supply of IVD kits, diagnostic reagents, medical diagnostic instruments and analysers. Its product portfolio includes CLIA, clinical chemistry and FIA-based diagnostic solutions.
4.	**Disclosure of relationships between directors**	Not applicable
5.	**Objects and impact of acquisition (including but not limited to disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)**	The acquisition is proposed with an objective to strengthen the Company's presence in the healthcare, medical diagnostics and IVD segment, expand its diagnostic product and technology offerings, leverage Matrix Labs R&D and manufacturing capabilities, achieve strategic and operational synergies and enhance long-term shareholder value.
6.	**Brief details of any governmental or regulatory approvals required for the acquisition.**	The proposed acquisition is subject to receipt of such statutory, regulatory and other approvals, consents and permissions as may be applicable to the transaction.
7.	**Indicative time period for completion of acquisition**	Up to 6 months, subject to receipt of necessary statutory and regulatory approvals and fulfilment of the terms and conditions of the definitive transaction documents.
8.	**Nature of consideration – whether cash consideration or share swap or any other form and details of the same**	The acquisition shall be undertaken by way of issuance and allotment of equity shares of the Company on a preferential basis for consideration other than cash through a share swap arrangement, for acquisition of up to 2,550 (Two Thousand Five Hundred Fifty Only) equity shares representing 51% of the diluted paid-up equity share capital of MLPL.
9.	**Cost of acquisition and/or the price at which shares are acquired**	The consideration shall be discharged by way of issuance of 64,440 (Sixty-Four Thousand Four Hundred Forty Only) equity shares of the Company pursuant to the share swap

		arrangement, as determined on the basis of the valuation reports and definitive transaction documents.
10.	**Percentage of shareholding/control acquired and/or number of shares acquired**	The Company proposes to acquire 2,550 (Two Thousand Five Hundred Fifty Only) equity shares of MLPL, representing 51% of the diluted paid-up equity share capital of the MLPL. Upon completion of the transaction, MLPL shall become a subsidiary of the Company.
11.	**Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)**	MLPL was incorporated on 30th January, 2014 and is an unlisted private company registered with the Registrar of Companies, Chennai. The Company operates in the medical equipment and in-vitro diagnostics (IVD) sector. It was established as a supplier of IVD kits and instruments and subsequently expanded into in-house research and development and manufacturing of diagnostic products. Its product portfolio includes chemiluminescence immunoassay (CLIA) systems, clinical chemistry reagents and analysers, fluorescence immunoassay (FIA) systems and other IVD kits and diagnostic instruments. The Company has its presence in India, with operations based in Chennai, Tamil Nadu. **Date of Incorporation:** 30th January, 2014 **Financial Year** — **Turnover (Rs. in Crore)** 2022-23 — 2.42 2023-24 — 4.91 2024-25 — 8.92 **Country of presence:** India **Any other significant information:** Nil

Financial Year	Turnover (Rs. in Crore)
2022-23	2.42
2023-24	4.91
2024-25	8.92

ANNEXURE D1

(Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, or the master circular in force on the date of filing)

Sr.No.	Particulars	Details
1.	**Name(s) of parties with whom the agreement is entered**	The Company has proposed to enter into the Share Purchase Agreement **("SPA")** with Matrix Labs Diagnocare Private Limited **("MLDPL")**, Mr. Suresh, Ms. Nithya S and One Global Service Provider Limited, subject to the approval of the shareholders of the Company.
2.	**Purpose of entering into the agreement**	The purpose of entering into the SPA is to facilitate the acquisition of the equity shares of MLDPL by One Global Service Provider Limited, thereby enabling the Company to expand and strengthen its presence in the diagnostic, pathology and allied healthcare services sector.
3.	**Size of agreement**	The total transaction value/consideration for the proposed acquisition is Rs.35,97,81,800/- (Rupees Thirty-Five Crore Ninety-Seven Lakh Eighty-One Thousand Eight Hundred Only). The consideration for acquisition is proposed to be discharged through issuance and allotment of equity shares of the Company on a preferential basis to the selling shareholders, subject to applicable laws and receipt of requisite approvals.
4.	**Shareholding, if any, in the entity with whom the agreement is executed.**	Nil
5.	**Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.**	The SPA sets out the terms and conditions governing the proposed acquisition of the equity shares of MLDPL by the Company, including the number of equity shares proposed to be acquired, consideration payable, representations and warranties of the parties, conditions precedent, completion/closing obligations, confidentiality and other customary terms and conditions. The acquisition is proposed to be completed subject to fulfilment of the conditions precedent and receipt of applicable statutory, regulatory and corporate approvals.
6.	**Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship.**	The proposed acquisition does not fall within the purview of related party transaction. Further, the promoter/promoter group/group companies of the Company do not have any interest in the entity being acquired.
7.	**Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"**	Not Applicable
8.	**In case of issuance of shares to the parties, details of issue price, class of shares issued**	The Company proposes to issue, offer and allot 6,01,760 (Six Lakh One Thousand Seven Hundred Sixty Only) and 48,840 (Forty Eight Thousand Eight Forty) fully paid-up equity shares of the Company, having a face value of Rs. 10/- each (Rupees Ten Only), at an issue price of Rs. 553/-

		(Rupees Five Hundred Fifty-Three Only) per equity share, aggregating to Rs. 35,97,81,800/- (Rupees Thirty-Five Crore Ninety-Seven Lakh Eighty-One Thousand Eight Hundred Only), to Mr. Suresh and Ms. Nithya S, respectively, as consideration for the acquisition of equity shares of MLDPL. The issue price shall not be less than the price determined in accordance with Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended from time to time, and other applicable laws.
9.	**In case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis.**	Not Applicable
10.	**Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.**	Not Applicable
11.	**In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): (i) name of parties to the agreement; (ii) nature of the agreement; (iii)date of execution of the agreement; (iv)details of amendment and impact thereof or reasons of termination and impact thereof**	Not Applicable

ANNEXURE D2

(Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, or the master circular in force on the date of filing)

Sr.No.	Particulars	Details
1.	**Name(s) of parties with whom the agreement is entered**	The Company has proposed to enter into the share purchase agreement **("SPA")** with Matrix Labs Private Limited **("MLPL")**, Mr. Suresh, and One Global Service Provider Limited, subject to the approval of the shareholders of the Company.
2.	**Purpose of entering into the agreement**	The purpose of entering into the SPA is to facilitate the acquisition of the equity shares of MLPL by One Global Service Provider Limited, thereby enabling the Company to expand and strengthen its presence in the diagnostic, pathology and allied healthcare services sector.
3.	**Size of agreement**	The total transaction value/consideration for the proposed acquisition is Rs. 3,56,35,320/- (Rupees Three Crore Fifty-Six Lakh Thirty-Five Thousand Three Hundred Twenty Only). The consideration for acquisition is proposed to be discharged through issuance and allotment of equity shares of the Company on a preferential basis to the selling shareholders, subject to applicable laws and receipt of requisite approvals.
4.	**Shareholding, if any, in the entity with whom the agreement is executed.**	Nil
5.	**Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.**	The SPA sets out the terms and conditions governing the proposed acquisition of the equity shares of MLPL by the Company, including the number of equity shares proposed to be acquired, consideration payable, representations and warranties of the parties, conditions precedent, completion/closing obligations, confidentiality and other customary terms and conditions. The acquisition is proposed to be completed subject to fulfilment of the conditions precedent and receipt of applicable statutory, regulatory and corporate approvals.
6.	**Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship.**	The proposed acquisition does not fall within the purview of related party transaction. Further, the promoter/promoter group/group companies of the Company do not have any interest in the entity being acquired.
7.	**Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"**	Not Applicable
8.	**In case of issuance of shares to the parties, details of issue price, class of shares issued**	The Company proposes to issue, offer and allot 64,440 (Sixty-Four Thousand Four Hundred Forty Only) fully paid-up equity shares of the Company, having a face value of Rs. 10/- each (Rupees Ten Only), at an issue price of Rs.

		553/- (Rupees Five Hundred Fifty-Three Only) per equity share, aggregating to Rs. 3,56,35,320/- (Rupees Three Crore Fifty-Six Lakh Thirty-Five Thousand Three Hundred Twenty Only), to Mr. Suresh, as consideration for the acquisition of equity shares of MLPL. The issue price shall not be less than the price determined in accordance with Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended from time to time, and other applicable laws.
9.	**In case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis.**	Not Applicable
10.	**Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.**	Not Applicable
11.	**In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): (i) name of parties to the agreement; (ii) nature of the agreement; (iii)date of execution of the agreement; (iv)details of amendment and impact thereof or reasons of termination and impact thereof**	Not Applicable

ANNEXURE - E

(Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, or the master circular in force on the date of filing)

<table>
<tr><th>Sr.No.</th><th>Particulars</th><th>Details</th></tr>
<tr><td>1.</td><td>Type of securities proposed to be issued (viz. equity shares, convertibles etc.)</td><td>Equity shares of face value Rs. 10/- (Rupees Ten Only) each</td></tr>
<tr><td>2.</td><td>Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)</td><td>Preferential issue of equity shares in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("ICDR Regulations"), read with the Companies Act, 2013 and rules made thereunder.</td></tr>
<tr><td>3.</td><td>Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)</td><td>The Company will issue, offer and allot 7,15,040 (Seven Lakh Fifteen Thousand Forty Only) equity shares of the Company having face value of Rs. 10/- (Rupees Ten Only) each, which is not less than the price determined in accordance with Chapter V of the ICDR Regulations, for consideration other than cash, as discharge of the non-cash consideration for the purchase of 51% of the total issued, subscribed and paid-up equity share capital of Matrix Labs Diagnocare Private Limited and Matrix Labs Private Limited from Mr. Suresh and Mr. Nithya S and Mr. Suresh, respectively.</td></tr>
<tr><td>4.</td><td colspan="2">Additional Details</td></tr>
<tr><td>(a)</td><td>Name of the investor</td><td>
<table>
<tr><th colspan="6">Matrix Labs Diagnocare Private Limited (MLDPL)</th></tr>
<tr><th>Sr. No.</th><th>Name of Proposed Allottees</th><th>% Stake in MLDPL</th><th>No. of Shares of MLDPL proposed to be transferred to Company</th><th>No. of shares of One Global Service Provider Limited proposed to be allotted for the acquisition of MLDPL shares</th><th>Name of Ultimate Beneficiaries / Owners</th></tr>
<tr><td>1.</td><td>Mr. Suresh</td><td>95%</td><td>12,321</td><td>6,01,760</td><td>Not Applicable</td></tr>
<tr><td>2.</td><td>Mr. Nithya</td><td>5%</td><td>1000</td><td>48,840</td><td>Not Applicable</td></tr>
</table>
</td></tr>
</table>

ONE GLOBAL SERVICE PROVIDER LIMITED
(Formerly known as Overseas Synthetics Limited)
CIN : L74110MH1992PLC367633
Telephone : 8657527323 Website : www.1gsp.in E-mail : 1connect@1gsp.in
Registered Address : 6th Floor, 601 E Wing, Trade Link Building, B & C Block, Senapati Bapat Marg, Kamla Mill Compound, Lower Parel (W) Mumbai 400013

<table>
<tr><td></td><td></td><td>
<table>
<tr><th colspan="6">Matrix Labs Private Limited (MLPL)</th></tr>
<tr><th>Sr.No.</th><th>Name of Proposed Allottees</th><th>% Stake in MLDPL</th><th>No. of Shares of MLDPL proposed to be transferred to Company</th><th>No. of shares of One Global Service Provider Limited proposed to be allotted for the acquisition of MLDPL shares</th><th>Name of Ultimate Beneficiaries / Owners</th></tr>
<tr><td>1.</td><td>Mr. Suresh</td><td>70%</td><td>2,550</td><td>64,440</td><td>Not Applicable</td></tr>
</table>
</td></tr>
<tr><td>(b)</td><td>Number of investors</td><td>Two</td></tr>
<tr><td>(c)</td><td>Issue Price</td><td>Rs. 553/- (Rupees Five Hundred Fifty-Three Only) (Face Value of Rs. 10/- (Rupees Ten Only) each at a Premium of Rs. 543/- (Rupees Five Hundred Forty-Three Only) per Equity Share fully paid-up.</td></tr>
<tr><td>(d)</td><td>Post allotment of securities - outcome of the subscription, issue price or allotted price, number of investors</td><td>Details of the shareholding of Mr. Suresh and Ms. Nithya S in the Company, prior to and after the proposed preferential issue are as under:
<table>
<tr><th rowspan="2">Name of Proposed Allottee</th><th colspan="2">Pre-Preferential Issue</th><th rowspan="2">No. of Equity Shares proposed to be allotted</th><th colspan="2">Post Preferential Issue</th></tr>
<tr><th>No. of Equity Shares</th><th>%</th><th>No. of Equity Shares</th><th>%</th></tr>
<tr><td>Mr. Suresh</td><td>--</td><td>--</td><td>6,66,200</td><td>6,66,200</td><td>3.29%</td></tr>
<tr><td>Mr. Nithya S</td><td>--</td><td>--</td><td>48,840</td><td>48,840</td><td>0.24%</td></tr>
</table>
</td></tr>
<tr><td>(e)</td><td>In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument</td><td>Not Applicable</td></tr>
<tr><td>5.</td><td>Any cancellation or termination of proposal for issuance of securities including reasons thereof</td><td>Not Applicable</td></tr>
</table>

ANNEXURE - F

(Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI LODR Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, or the master circular in force on the date of filing)

Sr.No.	Particulars	Description
1.	**Amendments to Memorandum of Association of listed entity, in brief**	Pursuant to the proposed increase in the Authorised Share Capital of the Company, subject to the approval of the shareholders of the Company, it is proposed to alter the capital clause of the Company from 25,05,00,000/- (Rupees Twenty-Five Crore Five Lakh Only) divided into 2,50,50,000 (Two Crore Fifty Lakh Fifty Thousand) Equity Shares of Rs. 10/- (Rupees Ten Only) each, to Rs.50,00,00,000/- (Rupees Fifty Crore Only) divided into 5,00,00,000 (Five Crore) Equity Shares of Rs. 10/- (Rupees Ten Only) each Capital Clause (Clause V) of the Memorandum of Association shall be altered as follows: ***V. The Authorised Share Capital of the Company is Rs. 50,00,00,000/- (Rupees Fifty Crore Only) divided into 5,00,00,000 (Five Crore) Equity Shares of Rs.10/- (Rupees Ten Only) each.***